December 2, 2019 – Buprenorphine, which won FDA approval in 2002 to combat opioid addiction, is dispensed to almost one million individuals annually. However, an estimated 50% to 80% of patients discontinue the treatment within several weeks or months, and there is no consensus about how long patients should continue taking the medication although expert consensus supports indefinite use.
Further, many insurance plans limit treatment with buprenorphine to six months or require approvals to be reauthorized every year, and patients who are at risk for incarceration are frequently deprived of buprenorphine treatment while awaiting arraignment or sentencing.
GIVING BACK IN STYLE – April 17, 2024 - “It’s still one day at…
RIDING THE WAVE...CALMLY – April 18, 2024 - “I was 13 years old and…
VIDEO – NEW YORK STORIES – April 23, 2024 - Sara Gettelfinger had steadily…
TRY IT, YOU’LL LIKE IT – April 18, 2024 - The rise in “sober…
AUDIO – SOBER MEN CAN DO THAT – April 4, 2024 - Acting icon…
I’LL BET HE GOES TO GA (not Georgia) – April 13, 2024 -The initial…